Delivery Order SPE2DB22D3004-SPE2DB24FRS30

Award Date 9/3/24
Potential Completion Date 9/4/24
Potential Value $7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,179.64 firm-fixed-price contract is for the supply of Emgality 120 mg/ml pens, a prescription medication. The contract has a period of performance through September 12, 2024. This order is part of AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,416.16 firm-fixed-price delivery order is for the supply of Emgality 120 mg/ml pen injector medication, with a period of performance through July 12, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,063.82, is for the delivery of Emgality 120 mg/ml Penml, a medication, on a firm fixed price basis. The contract has an ultimate completion date of June 26, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a $1,361.60 Delivery Order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of pharmaceutical products, including EMGALITY 120 MG/ML PENML. The award is not set aside and is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of medical commodities to support military treatment programs and...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,729.00, is for the delivery of the pharmaceutical product Emgality 120 mg/ml pen. The contract has an ultimate completion date of December 20, 2024 and is a firm fixed-price delivery order. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Emgality 120 mg/ml pens. The contract has a ceiling value of $1,002.72 and runs through August 5, 2024. AmerisourceBergen provides a wide range of pharmaceutical and medical products to various government agencies and healthcare programs, including the military and veterans' hospitals. The company holds several...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,005.44 firm fixed-price contract is for the supply of Emgality, a 120 mg/mL injectable medication, to support military healthcare programs. The contract has an ultimate completion date of November 8, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,597.52 firm fixed-price delivery order is for the medication Emgality 120 mg/ml penml, with a performance period ending on May 6, 2025. The contract is not set aside and is considered an open competition award. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the medication Emgality (galcanezumab-gnlm) 120 mg/mL pen. The fixed-price contract has a ceiling value of $1,567.26 and a completion date of May 30, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,729.00, is for the delivery of Emgality 120 mg/ml pen injectors. The contract is a Firm Fixed Price Delivery Order that runs through March 27, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB24FRS30
    Delivery Order

This is a delivery order valued at $6,992.72 awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Emgality 120 mg/ml pens. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. This delivery order does not have a set-aside designation and is expected to be completed by September 4, 2024.

Generated 12/3/24, 9:49 AM